Columbia, Mo.-based University of Missouri Health Care has purchased the inventory of a Versailles, Mo.-based pharmacy that recently closed its doors, according to a Dec. 19 report from NBC affiliate KOMU.  

After the FDA reaffirmed the end of Zepbound's two-year shortage, drug companies have announced shortages for 32 presentations of seven medications. 

Becker's asked pharmacy executives from hospitals and health systems across the U.S. to share the areas they're focusing on for 2025.

Zepbound, Eli Lilly's weight loss medication, became the first FDA-approved drug for obstructive sleep apnea Dec. 20. 

Nearly three years after its launch, Mark Cuban Cost Plus Drug Co. now manufactures injectables in shortage, works with thousands of healthcare facilities, including pharmacies, hospitals, long-term care sites and clinics, and offers more than 2,000 discounted generics and about…

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the production of compounded versions of the…

A surge of vaccine and countermeasure claims hit an HHS program during the COVID-19 pandemic, and only about 26% of those claims have been processed, according to a Dec. 18 federal report. 

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535. 

A study published Nov. 24 in Arthritis Care & Research highlighted serious health risks associated with the use of oral acetaminophen in adults over 60. 

Hershey, Pa.-based Penn State Health has named Sam Wetherill, PharmD, as its next vice president and chief pharmacy officer, effective Dec. 30.